[High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas].
Metastatic sarcomas have a poor prognosis with current therapeutic regimens. High dose chemotherapy (HDC) has proved to be efficient in a selected group of solid tumors. Nine patients with high grade metastatic sarcomas were treated with HDC followed by autologous bone marrow transplantation. Four patients received HDC as a consolidation of the complete response (CR) obtained with chemotherapy (CT) and two of them were free from disease at 27 and 41 months, respectively. Other four patients had a disease total or partially refractory to conventional CT, and in one case the sensitivity to the chemotherapeutical agents was unknown. In these five cases a partial response was observed in two of the three who had measurable response parameters, but all of them died because of disease progression in a short period of time. These results suggest that there are active HDC schedules on metastatic sarcomas, but its possible benefit would be limited to the consolidation of a CR obtained with previous CT. HDC is a therapeutical alternative under investigation in patients with metastatic sarcomas with an indication that could be extended to cover localized sarcomas with poor prognosis.
Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau., Barcelona.
R
R
Mesía
C
C
Solá
A
A
López Pousa
L
L
Mendoza
M
M
Bellet
L
L
Andrés
J J
JJ
López López
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012509:Sarcoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D014182:Transplantation, Autologous
Quimioterapia con altas dosis y trasplante autólogo de médula ósea en sarcomas de alto grado metastásicos.